Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Ram Selvaraju has given his Hold rating due to a combination of factors surrounding Kezar Life Sciences. The company recently received an unsolicited and non-binding purchase proposal from Concentra ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Kezar Life Sciences (KZR – Research Report).

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

On Thursday, Kezar Life Sciences Inc (KZR) stock saw a decline, ending the day at $0.82 which represents a decrease of $-0.07 or -7.87% from the prior close of $0.89. The stock opened at $0.86 and ...

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan ...